Ryan Haumschild, PharmD, Advises Practices, Health Systems to Prep for Interchangeable Biosimilars
June 5th 2022Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives an overview of what practices and health systems need to prepare for as more interchangeable biosimilars enter the US market.
Julie Reed Catalogues Actions Needed to Ensure Biosimilars Benefit Patients
May 29th 2022Combatting misinformation surrounding interchangeability and incentivizing biosimilars are just some of the many things that can be done to ensure patients benefit from biosimilars savings, said Julie M. Reed, the executive director of the Biosimilars Forum.
Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology
May 22nd 2022The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.
Dr Eric Tichy Calls for Government Officials to Realign Incentives in Favor of Biosimilars
May 18th 2022Altering reimbursement procedures needs to become a bigger priority for government officials to incentivize biosimilar utilization, according to Eric Tichy, PharmD, MBA, vice chair of pharmacy formulary at the Mayo Clinic Health System.
Health IT for Biosimilars Spotlight: Cardinal Health's Decision Pathway
May 10th 2022Amy Valley, vice president of clinical strategy and technology solutions at Cardinal Health, details the company's Decision Pathway, a health information technology (IT) tool that can assist practices with prescribing patients the lowest-cost product, including biosimilars.
Dr Sonia Oskouei Describes the Need for More Biosimilar Education for Ophthalmologists
May 8th 2022Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.
Julie Reed: House Hearing Omitted Biosimilar Issues Despite Growing Need for Solutions
May 4th 2022The main takeaway from the House Energy and Commerce Committee hearing on HHS's 2023 budget was that biosimilars were not mentioned as much as they should have been, said Julie M. Reed of the Biosimilars Forum.
Dr Edward Arrowsmith Discusses Clinical Pathways, Biosimilars in Ensuring Quality of Care
April 5th 2022Edward Arrowsmith, MD, discussed his recent paper on the use of clinical pathways for specific cancer types and how biosimilar development can help ensure quality of care for patients with limited therapeutic options.
Dr Chelsee Jensen and Dr Eric Tichy Discuss the Mayo Clinic's Success With Biosimilar Adoption
April 3rd 2022Chelsee Jensen, PharmD, and Eric Tichy, PharmD, MBA, who coauthored a paper on the Mayo Clinic's success with implementing biosimilars, discuss their study and how their practice is expected to evolve to improve its approach.
Gillian Woollett Gives Insight Into What the US Can Learn From Europe's Biosimilar Adoption
March 29th 2022Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, explains why there's no easy to solution to getting the US biosimilar market to the same level as Europe.
Jeffery Casberg Previews His Presentations at AMCP 2022
March 27th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.